A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension

NCT01518998 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
420
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Boryung Pharmaceutical Co., Ltd

Collaborators